Tumor mutational burden is an emerging biomarker to predict response to immune checkpoint inhibitors, but its utility as a prognostic indicator in ovarian cancer is unclear.
Understanding the tumor mutation burden (TMB) genetic signature in patients with ovarian cancer may predict their response to immunotherapy, according to a recent study in International Immunopharmacology.
TMB is an emerging biomarker to predict response to immune checkpoint inhibitors (ICIs), but its utility as a prognostic indicator in ovarian cancer is unclear.
Response to immune checkpoint inhibitors—programmed cell death-ligand 1 (PD-L1), programmed cell death 1 (PD1), and cytotoxic T lymphocyte antigen 4 (CTLA4)—have not been as successful in patients with ovarian cancer compared with lung cancer and melanoma.
Given that TMB can predict ICI response, and high TMB may be linked with better response to CTLA4, PD1 or PD-L1, as well as combination therapy, the authors of this study sought to examine the prognostic value of TMB and any correlations with response to immune therapy and immune cell infiltration in ovarian cancer.
The researchers used patient samples from 3 datasets to create a genetic signature: 587 patients from The Cancer Genome Atlas (TCGA), 260 patients from the GSE32062, and 94 patients from the International Cancer Genome Consortium (ICGC).
Patients from TCGA dataset were used as a training cohort, and the datasets from GSE32062 and ICGC were used for validation.
The TMB for each patient was estimated as the number of variants per exon length, and was merged with the corresponding clinical data (outcomes, immune infiltrates, and immunotherapy responsiveness) from each patient. Patients from the TCGA dataset (the training group) were divided into high- and low-TMB groups according to their median TMB.
Higher TMB was associated with better survival in the TCGA and ICGC OC cohorts. The high-TMB group had higher CD8+ T-cell infiltration than the low-TMB group.
While no significant correlation was found between TMB and immunotherapy response was found, further analysis suggested that patients in the low-risk group might have a better response to anti-PD1 therapy.
Using weighted gene co-expression network analysis, the researchers identified 8 prognostic and TMB-related genes to construct a TMB-related signature that could distinguish between the high- and low-risk patients. Its predictive power was validated in the GSE32062 and ICGC datasets.
Among the 8 genes, RAB34, CDH22, and LRRC4B were associated with higher risk; the remaining 5 (CAMK1G, ISG20, HLA-DOB, USP51, and PRSS16) were identified as protective factors.
Further work needs to use a larger sample size of patients in a prospective study; in addition, the researchers said experiments such as flow cytometry and immunohistochemistry are necessary to verify the relationship between the TMB and TMB-related genes and immune cell infiltration.
Reference
Fan S, Gao Xm Qin Q, Li H, Yuan Z, Zhao S. Association between tumor mutation burden and immune infiltration in ovarian cancer. Published online November 11, 2020. Int Immunopharmacol. doi: 10.1016/j.intimp.2020.107126
Study Reveals Link Between Ovarian Cancer, Subsequent Dry Eye Disease Incidence
May 13th 2024Patients diagnosed with ovarian cancer (OC), particularly those older than 60 years or with a disease duration exceeding 5 years, had a higher incidence of subsequent dry eye disease (DED), suggesting a potential correlation between OC and DED.
Read More
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More